Publications

The VALIDATE Network: Accelerating Vaccine Development for Tuberculosis, Leishmaniasis, Melioidosis and Leprosy

Vermaak S. et al, (2023), Vaccines for Neglected Pathogens: Strategies, Achievements and Challenges: Focus on Leprosy, Leishmaniasis, Melioidosis and Tuberculosis, 11 - 25

A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults.

Wilkie M. et al, (2020), Vaccine, 38, 779 - 789

Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial.

Manjaly Thomas Z-R. et al, (2019), PLoS medicine, 16

A CLINICAL CHALLENGE TRIAL DELIVERING AEROSOL BCG AS A CONTROLLED HUMAN INFECTION IN HEALTHY BCG-NAIVE, UK ADULTS: ESTABLISHING OPTIMAL DOSE AND EVALUATING SAFETY

Marshall JL. et al, (2019), AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 101, 368 - 369

Lessons from the first clinical trial of a non-licensed vaccine among Ugandan adolescents: a phase II field trial of the tuberculosis candidate vaccine, MVA85A

Wajja A. et al, (2018)

VALIDATE: Exploiting the synergy between complex intracellular pathogens to expedite vaccine research and development for tuberculosis, leishmaniasis, melioidosis and leprosy

Fletcher HA. et al, (2018), F1000Research, 7, 485 - 485

Lessons from the first clinical trial of a non-licensed vaccine among Ugandan adolescents: a phase II field trial of the tuberculosis candidate vaccine, MVA85A.

Wajja A. et al, (2018), Wellcome open research, 3

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial

Wajja A. et al, (2017), PLOS Neglected Tropical Diseases, 11, e0005440 - e0005440

A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults

Minhinnick A. et al, (2016), Vaccine, 34, 1412 - 1421

Optimization of a Human Bacille Calmette-Guérin Challenge Model: A Tool to Evaluate Antimycobacterial Immunity

Minhinnick A. et al, (2016), Journal of Infectious Diseases, 213, 824 - 830

S40 Optimisation of a human BCG challenge model

Wilkie MEM. et al, (2015), Thorax, 70, A27.1 - A27

A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults

Sheehan S. et al, (2015), PLOS ONE, 10, e0141687 - e0141687

Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial

Ndiaye BP. et al, (2015), The Lancet Respiratory Medicine, 3, 190 - 200

The Candidate TB Vaccine, MVA85A, Induces Highly Durable Th1 Responses

Tameris M. et al, (2014), PLoS ONE, 9, e87340 - e87340

Two Doses of Candidate TB Vaccine MVA85A in Antiretroviral Therapy (ART) Naïve Subjects Gives Comparable Immunogenicity to One Dose in ART+ Subjects

Dieye TN. et al, (2013), PLoS ONE, 8, e67177 - e67177

Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial

Tameris MD. et al, (2013), The Lancet, 381, 1021 - 1028

Capacity building for tuberculosis vaccine clinical trials in South Africa and Senegal

Vermaak S., (2012), TROPICAL MEDICINE & INTERNATIONAL HEALTH, 17, 39 - 39

Cookies on this website

Publications